AxoGen, Inc. (NASDAQ: AXGN) is a Healthcare company (Medical - Devices) with a market capitalization of $3.5B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), AxoGen, Inc. had a Maz Rating of 4.72 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Financial Health (4.74), among the strongest in its sector; its weakest was Valuation (1.41), among the most expensive in its sector. The other factors: Momentum 4.60 (among the strongest in its sector); Profitability 4.21 (above most of its sector); Growth 3.19 (around the middle of its sector). The current rating is for members: log in to see it.
At $58.63, AxoGen, Inc. trades at 11.4x sales and 5.7x book value. Over the last twelve months it generated about $308M of revenue and a net loss of $45M. It runs a gross margin of 74.2%, an operating margin of -5.2% and a net margin of -12.0%. It shows return on equity of -11.3%, return on invested capital of -2.7% and a free cash flow yield of 0.5%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 12.02. Over the past 52 weeks the share price ranged from $23.00 to $59.72, with a beta of 1.17.
AxoGen, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 19 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.